Nektar Therapeutics Announces It Will Regain Full Rights To Rezpegaldesleukin, A Novel, First-In-Class Selective Regulatory T-cell Therapy In Clinical Development
Company plans to move REZPEG forward into Phase 2 clinical study in atopic dermatitis
SAN FRANCISCO, April 27, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.